Skip to content

Machine Learning Assessment of Next-Day Migraine Likelihood

Machine Learning Assessment Of Next-Day Migraine Likelihood Collected Via The Nerivio App

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT07227194
Enrollment
53065
Registered
2025-11-12
Start date
2025-02-07
Completion date
2025-08-20
Last updated
2025-11-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Migraine

Keywords

Migraine treatment, Machine learning, Nerivio app

Brief summary

Development of a machine learning (ML) algorithm for assessment of next-day migraine likelihood, drawing on self-reported migraine-related information, and geographic location, collected via the Nerivio app- a mobile application used for migraine treatment by the Remote Electrical Neuromodulation (REN) wearable device.

Detailed description

The analysis set includes patients with migraine who used Nerivio app for the reporting of migraine attacks and/or associated symptoms and/or migraine-related information. Data collection is through the Nerivio app (Nerivio®). During app registration, patients consent to the collection of de-identified data for research purposes and provide demographic information. Participants can voluntarily report baseline characteristics such as treatment onset time relative to attack onset, headache pain, functional disability, and presence/absence of migraine-associated symptoms, as well as treatment outcomes 2-hours post-treatment. All data is stored on a HIPAA-compliant secure server. The algorithm will be trained on user-level data. The dataset will be structured as a tabular matrix, where the columns represent risk-related features and the rows represent user-day observations. The feature set (X) serves as input variables, while the migraine occurrence label (Y) is the target outcome. The feature set (X) could be divided into four groups, according to the data source: Demographic data - age and sex were self-reported via the app upon registration. The user's country is identified based on IP address. Questionnaire data - features which are the patient's answers to either the daily diary questionnaire or a pre-treatment questionnaire. These include headache severity, functional disability, medication intake, aura, pain duration, and prodromal symptoms. Data on prodromal symptoms is collected via a multiple-choice question with 14 pre-defined answers. Weather data - environmental features that are based on users' geographic location. These include barometric pressure, temperature, heat index, UV index, wind, humidity, and precipitation. Calculated features - features that are calculated based on the aforementioned collected data. These include averages, frequencies, number of consecutive days, etc'. Label (Y) Definition - The target variable (Y) will be defined using daily diary entries and pre-treatment questionnaires. The next-day migraine field served as the target outcome. A value of 1 (migraine day) will be assigned if a migraine was reported on the subsequent calendar day; a value of 0 (non-migraine day) will be assigned if no migraine was reported. Missing values were kept as null to capture potential information inherent in their non-random occurrence. A day is classified as a migraine day (Y = 1) if both of the following conditions were met: A) Headache level was reported as mild, moderate, or severe in the diary or pre-treatment questionnaire. B) At least one additional migraine indicator was present: intake of migraine-related medication, or report of photophobia, phonophobia, nausea and/or vomiting, or aura in the diary or pre-treatment questionnaire. The following standard ML outcome measures were used to evaluate model performance: Precision- the percentage of migraine days correctly predicted, out of all predicted days. Accuracy- the percentage of days correctly predicted (migraine and non-migraine), out of all the predicted days. Sensitivity (also termed recall rate)- the percentage of migraine days correctly predicted, out of all the migraine days. Specificity- the percentage of non-migraine days correctly predicted, out of all the non-migraine days. Area Under the Curve (AUC)- the probability that the model ranks a migraine day higher than a non-migraine day, based on predicted risk scores (summarizing the model's ability to distinguish between migraine and non-migraine days across all classification thresholds). F1 score- the balance between correctly predicted migraine days and avoiding wrongly-predicted migraine days, combining sensitivity and precision in one measure.

Interventions

None listed

Sponsors

WCG IRB
CollaboratorUNKNOWN
Theranica
Lead SponsorINDUSTRY

Study design

Observational model
OTHER
Time perspective
RETROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
8 Years to No maximum
Healthy volunteers
No

Inclusion criteria

1. \- Nerivio users age 8 and above. 2. \- Filled at least 2 daily diaries/ pre-treatment reports via the Nerivio app during the same month.

Exclusion criteria

* NA

Design outcomes

Primary

MeasureTime frameDescription
Precision of the prediction model24 hoursThe percentage of migraine days correctly predicted, out of all predicted days.

Secondary

MeasureTime frameDescription
Specificity of the prediction model24 hoursThe percentage of non-migraine days correctly predicted, out of all the non-migraine days
Sensitivity of the prediction model24 hoursThe percentage of migraine days correctly predicted, out of all the migraine days.
Accuracy of the prediction model24 hoursThe percentage of days correctly predicted (migraine and non-migraine), out of all the predicted days
Area Under the Curve (AUC)24 hoursThe probability that the model ranks a migraine day higher than a non-migraine day, based on predicted risk scores (summarizing the model's ability to distinguish between migraine and non-migraine days across all classification thresholds).
F1 score for the prediction model24 hoursThe balance between correctly predicted migraine days and avoiding wrongly-predicted migraine days, combining sensitivity and precision in one measure.

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026